News | February 20, 2021
Lupin receives approval for Droxidopa capsules
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness
India business grew 11.8% YoY vs mid-single digit industry growth.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The centralized marketing authorization granted by the EC is valid in all EU Member
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The company has posted net profit of Rs.397.06 crores for the 9 months period ended December 31, 2020.
The partnership is a significant step in delivering advanced cancer therapies to patients.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Subscribe To Our Newsletter & Stay Updated
